CMC review for China-origin biologics assets

Song Consultancy supports the evaluation of China-origin biologics assets for US or EU development. Frank reviews the CMC, manufacturing, and transfer-readiness questions that determine whether an asset can move forward outside China with a realistic development and supply plan. The same review works in reverse for a biologics program being prepared for US or EU development, identifying what CMC information, documentation, or process work may be required.

What Frank assesses

Frank reviews the CMC package, manufacturing process, process history, analytical and release strategy, cell line and upstream process information, data completeness, and technology transfer assumptions. The key question is not only whether the biology is attractive. The practical CMC question is whether the process is sufficiently understood, documented, controlled, and transferable to support US/EU development and future supply.

Scope includes

• CDMO selection & technology transfer
• CMC data-room review
• Manufacturing process and process-history review
• Cell line and upstream process review
• Analytical and release strategy review
• IND-facing CMC gap assessment
• Technology transfer readiness
• Supply planning outside China
• Mandarin technical clarification with the originator

What Frank does not do

Frank does not replace transaction counsel, financial diligence, commercial diligence, clinical diligence, regulatory counsel, or sponsor decision-making. His role is to support the technical CMC portion of the evaluation and work alongside legal, regulatory, clinical, and business teams as needed.

Why Song Consultancy

Frank brings a combination of hands-on biologics CMC experience, China operating experience, and Mandarin-English technical communication. His background spans cell line development, upstream process development, media formulation, technology transfer, and CMC execution across 20+ biologics programs, including mAbs, bispecifics, and ADCs. He also founded and led Eminence Biotechnology in Suzhou, giving him direct operating experience inside China's biotech ecosystem.

That combination matters because China-origin asset diligence often requires more than reviewing translated documents. Important process knowledge may sit with the originator's technical team, may not be fully captured in the written package, or may need to be clarified before the program can be transferred or developed outside China. Frank helps identify those gaps early and translate them into practical CMC, transfer, and supply-planning decisions.

Common questions